// App-Quantinova.ai

: Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

Researchers

Presenter

  • Audreylie Lemelin

Principal Investigators

  • Connor Wells

  • Vishal Navani

  • Bradley Alexander McGregor

  • Shirley S. Wong

  • Sumanta Monty Pal

  • Naveen S. Basappa

  • Anil Kapoor

  • Jae-Lyun Lee

  • Frede Donskov

  • Haoran Li

  • Takeshi Yuasa

  • Rose Chang

  • Lynn Huynh

  • Catherine Nguyen

  • Ashley Holub

  • Louise Clear

  • Mei Sheng Duh

  • Daniel Yick Chin Heng

Medical Centers

  • University Hospital of Southern Denmark, Vejle, Denmark

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

  • BC Cancer Agency, Vancouver, BC, Canada

  • Analysis Group, Inc., Boston, MA

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

  • Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada

  • City of Hope Comprehensive Cancer Center, Monrovia, CA

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Dana-Farber Cancer Institute, Boston, MA

  • Western Health Hospital, University of Melbourne, Brunswick, Australia

Locations

  • Republic of South Korea

  • Denmark

  • Canada

  • Japan

  • Australia

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

  • Solid malignancies

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved